Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm’s KP415, An Investigational Prodrug of D-Methylphenidate, Completes Phase 1 Proof-of-Concept Trial for the Treatment of ADHD
  Both Early and Extended Release of the Methylphenidate Prodrug was observed in the KP415.101 Study Conference Call and Live Audio Webcast with Dr. Scott Kollins Scheduled for Today at 4:30 p.m., ET CORALVILLE, Iowa , Dec. 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain
KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa , Nov. 29, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and
Toggle Summary KemPharm, Inc. Reports Third Quarter 2016 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m., ET Recent Clinical Development & Regulatory Highlights : Prioritized KP415 and KP201/IR as co-lead product candidates Received clearance from the U.S.
Toggle Summary KemPharm Appeals FDA Complete Response Letter on Apadaz™ by Initiating a Formal Dispute Resolution Process
CORALVILLE, Iowa , Nov. 03, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has appealed the Food and Drug Administration's ( FDA ) Complete Response Letter
Toggle Summary KemPharm Files IND for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain
KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa , Oct. 25, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and
Toggle Summary KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent Technology
Agreement focused on KemPharm's current and in-development IR Opioid Pipeline CORALVILLE, Iowa and PALATINE, Ill. , Oct. 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, and
Toggle Summary KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP415, an Investigational Prodrug of D-Threo-Methylphenidate for the Treatment of ADHD
KP415, KemPharm’s co-lead product candidate, is designed to be a predictably-dosed, extended release methylphenidate product CORALVILLE, Iowa , Oct. 11, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development
Toggle Summary KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate
KP415 is designed to be a predictably-dosed, extended release methylphenidate product CORALVILLE, Iowa , Sept. 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today
Toggle Summary KemPharm, Inc. Provides Corporate and Clinical Update
Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET KemPharm adjusts product development timelines following full pipeline analysis and positions KP415 and KP201/IR as lead product candidates to capitalize on favorable developmental, regulatory and market conditions Announces
Toggle Summary KemPharm, Inc. Reports Second Quarter 2016 Results
Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET Recent Clinical Development & Regulatory Highlights : Completed FDA End of Review meeting for Apadaz™ following receipt of Complete Response Letter Reported results from KP511 Phase 1 Proof-of-Concept Trial; Announces